International phase 3 clinical trial for new melanoma treatment recruits first patients
The INTerpath-001 trial is evaluating Moderna/Merck’s mRNA-4157 in combination with Merck’s Keytruda
Read More
Tag: Merck & Co
AZ/Merck’s Lynparza approved by SMC to treat advanced prostate cancer in Scotland
Up to 20% of prostate cancer cases are classified as castration-resistant
Read More
IO Biotech enrols 380 patients with advanced melanoma in phase 3 trial
The trial is evaluating an investigational cancer vaccine in combination with Keytruda
Read More
Merck to donate vaccine doses to IAVI for Sudan ebola virus
The International AIDS Vaccine Initiative is a global nonprofit scientific research organisation
Read More
Welireg approved in US for rare VHL-associated cancers
VHL is a rare genetic disease which puts patients at risk of developing benign blood vessel tumours and several cancers
Read More
Priority review for Merck & Co’s belzutifan in rare kidney cancer subset
Belzutifan is a potential treatment for von Hippel-Lindau disease-associated renal cell carcinoma
Read More
Speedy review for AZ’ Lynparza in breast cancer
AstraZeneca’s and MSD’s Lynparza is being given a priority review by US regulators as a potential treatment for breast cancer, marking the first time a PARP inhibitor has been filed for an indication outside of ovarian cancer.
Read More
AZ, Merck link to develop and commercialise cancer drugs
In a bumper news day for AstraZeneca, the firm announced a deal with Merck & Co to co-develop and co-commercialise Lynparza and selumetinib for multiple cancer types, second-quarter results in line with expectations, initial trial data showing the failure of Imfinzi to boost PFS in lung cancer patients, and other trial data in lung cancer showing the success of Tagrisso in improving PFS.
Read More
MSD’s CETP inhibitor lowers risk of cardiac events
MSD’s CETP inhibitor anacetrapib has hit its key target in the late-stage REVEAL study, showing a significant reduction in major coronary events in at-risk patients already on a cholesterol-lowering regimen.
Read More
Merck buys experimental tau antibody from Teijin
Merck & Co has bought itself an exclusive global licence from Teijin Pharma to develop, manufacture and commercialise an investigational preclinical antibody candidate targeting a protein called tau.
Read More
FDA rejects CV outcomes claim for Merck diabetes drugs
The US Food and Drug Administration has dealt Merck & Co a blow in turning down its request to have cardiovascular outcomes data added to the labels of its diabetes drugs Januvia and Janumet.
Read More
Merck files Keytruda for MSI-H cancer
Merck & Co has filed its immunotherapy Keytruda in the US as a potential therapy for previously treated patients with advanced microsatellite instability-high (MSI-H) cancer.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
